The second most frequently mutated CMG in both DLBCL and FL is the CREBBP gene, 87 which encodes a histone acetyltransferase that activates transcription via acetylation of 88 histone H3 lysine 27 (H3K27Ac) and other residues. We have previously found that these 89 mutations arise as early events during the genomic evolution of FL and reside in a 
MATERIALS AND METHODS

120
For detailed methodology, please refer to the supplementary methods section. Kits (Roche) and TruSeq adaptors (Bioo Scientific) using 6 cycles of PCR enrichment.
139
Libraries were 6-plexed and sequenced with 2x100bp reads on a HiSeq-4000 (Illumina).
140
The data were mapped using BWA, peaks called using MACS2, and differential analyses 141 performed using DiffBind. For gene set enrichment analyses, the gene with the closest 142 transcription start site to the peak was used. The statistical thresholds for significance 143 were q<0.05 and fold-change>1.5. 
RESULTS
188
CREBBP R1446C mutations function as a dominant-negative to suppress BCL6 co-189 regulated epigenetic and transcriptional programs. 190 The CREBBP gene is predominantly targeted by point mutations that result in single 191 amino acid substitutions within the lysine acetyltransferase (KAT) domain 6, 19 , with a 192 hotspot at arginine 1446 (R1446), which lead to a catalytically inactive protein 20, 21 .
193
However, all of the prior studies characterizing effects of CREBBP mutation have been Figure 1F ; Table S2 ). The genes that were proximal 230 to regions of H3K27Ac loss showed a coordinate reduction in transcript abundance and 231 vice versa (Figure 1G ), suggesting that these broad changes in transcription are directly 232 linked to altered promoter/enhancer activity as a result of differential H3K27Ac (52).
233
Importantly, we observed significant enrichment of the transcriptional signature that we 234 have previously characterized using shRNA knock-down of CREBBP in murine B-cells or 235 human DLBCL cell lines 7 , with genes that are down-regulated following shRNA knock-236 down also being significantly reduced in CREBBP mutants (FDR<0.05, Figure 1H ).
237
However, a more significant enrichment was observed for the signature of genes we 238 defined as being lost in association with CREBBP mutation in primary human FL B-cells 6
239
(FDR<0.001, Figure 1H ). This shows that these CRISPR/Cas9-edited clones closely 240 resemble the molecular phenotype of CREBBP mutations in primary B-cell lymphoma,
241
and therefore provides a tractable model for studying the functional consequences of 242 these mutations.
244
To provide insight into the pathways that are deregulated by CREBBP mutation, we used 245 hypergeometric analysis to identify sets of genes that were significantly deregulated by we expanded each tumor in vivo and transitioned them to our novel in vitro organoid 331 system for exposure to BRD3308 29 . All tumors that were tested showed a dose- The CREBBP gene is mutated in ~15% of DLBCL 21 and ~66% of FL 6 , and is therefore a we also noted that the same molecular signature is promoted by HDAC3 inhibition in 575 CREBBP wild-type cells, also with an associated increase of MHC class II expression.
576
As with the cell-intrinsic effects of HDAC3 inhibition, the effects on immune interactions 577 may therefore be active in both CREBBP wild-type and CREBBP mutant cells, as a result 578 of the conserved molecular circuitry controlling these pathways in each genetic context. anemia and neutropenia were frequent, and the responses tended not to be durable 37,38 .
584
We posit that specific inhibition of HDAC3 may be accompanied by reduced toxicity, as Gene set enrichment analysis shows that genes which were previously found to be down- 793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823 982  983  984  985  986  987  988  989  990  991  992  993  994  995  996  997  998  999  1000  1001  1002  1003  1004  1005  1006  1007  1008 H3K27Ac Loss
R1446C vs WT (n=2022)
H3K27Ac Gain
R1446C vs WT (n=2304)
Wild-type gRNA1 gRNA2 
CDKN1A
WT R1446C
BRD4097 µM WT gRNA1 WT gRNA2 R1446C gRNA1 R1446C gRNA2
BRD3308 10µM
IFNγ 10ng/mL * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
